Clinical Trial Update: Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck [Phase 2]

View source ↗

Summary

This Phase 2 trial update assesses dual EGFR inhibition with afatinib and cetuximab in advanced head and neck squamous cell carcinoma, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)
• Gilotrif (Afatinib)

Snippet

Sponsor: Yale University | Conditions: Squamous Cell Cancers of the Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2026-02-04